A carregar...
Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
Tyrosine kinase inhibitors (TKI), including imatinib (IM), improve the outcome of CML therapy. However, TKI treatment is long‐term and can induce resistance to TKI, which often leads to a poor clinical outcome in CML patients. Here, we examined the effect of continuous IM exposure on intracellular e...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765287/ https://ncbi.nlm.nih.gov/pubmed/29121435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13442 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|